An update of ALK inhibitors in human clinical trials

Eason Leong Yin Chan, Claudia Ho Yi Chin, Vivian Wai Yan Lui

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

The proto-oncogenic ALK is a druggable receptor tyrosine kinase for cancer treatment. Two small molecule inhibitors of ALK, crizotinib and ceritinib, have been recently approved for the treatment of metastatic non-small-cell lung cancer, with marked improvement of progression-free survival of patients. Independent case reports also indicate their potential therapeutic activity in other ALK-rearranged cancers. Numerous single-agent and combination therapy trials are ongoing in lung and many other cancers. Results of these trials are greatly anticipated. Here, we summarize our current understanding of ALK signaling, genomic aberrations in cancer and emerging mechanisms of drug resistance. We will also provide a timely review on all ALK inhibitors and their current status of development in clinical settings.

Original languageEnglish (US)
Pages (from-to)71-81
Number of pages11
JournalFuture Oncology
Volume12
Issue number1
DOIs
StatePublished - Jan 2016
Externally publishedYes

Keywords

  • ALK alterations
  • ALK inhibitor
  • resistance to ALK inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'An update of ALK inhibitors in human clinical trials'. Together they form a unique fingerprint.

Cite this